title: Dual therapy of rosiglitazone/pioglitazone with glimepiride on diabetic nephropathy in experimentally induced type 2 diabetes rats.
abstract: Diabetic nephropathy is a major cause of end-stage renal disease (ESRD) in the general population. It is estimated that diabetic nephropathy will eventually develop in about 40% of all patients with diabetes; therefore, prevention is critical for delaying the development and progression of diabetic kidney disease. Despite extensive efforts, medical advances are still not successful enough to prevent the progression of the disease. In the present study, we focused on the comparison of combination therapies and whether they offered additional renoprotection. Type 2 diabetes mellitus was induced by intraperitoneally administering streptozotocin (90 mg/kg) in neonatal rats and then these rats were treated with rosiglitazone (1.0 mg/kg) in combination with glimepiride (0.5 mg/kg) or with pioglitazone (2.5 mg/kg) in combination with glimepiride (0.5 mg/kg). Diabetic nephropathy markers were evaluated by biochemical and ELISA kits and renal structural changes were examined by light microscopy and transmission electron microscopy. Results show that the combination of pioglitazone with glimepiride is more effective in amelioration of diabetic nephropathy than rosiglitazone with glimepiride drug therapy due to glycemic control, suppressing albumin excretion rate, total protein excretion rate and augmented TNF-a signaling during the development of streptozotocin induced type 2 diabetic nephropathy.
authors.affiliation: Department of Pharmacology, Delhi Institute of Pharmaceutical Sciences and Research (DIPSAR), New Delhi 110017, India;
authors.forename: Ravi Prakash
authors.initials: RP
authors.lastname: Rao
authors.forename: Ansima
authors.initials: A
authors.lastname: Singh
authors.forename: Arun K
authors.initials: AK
authors.lastname: Jain
authors.forename: Bhartu Parsharthi
authors.initials: BP
authors.lastname: Srinivasan
keywords: diabetic nephropathy; peroxisome proliferator activated receptors (PPARs); transforming growth factor-β1 (TGF-β1); tumor necrosis factor-α (TNF-α); type 2 diabetes mellitus
references.citation: Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1814-8
references.pmid: 7680480
references.citation: Diabetes. 2007 Aug;56(8):2036-45
references.pmid: 17536062
references.citation: Diabetes. 1981 Jan;30(1):64-9
references.pmid: 6112177
references.citation: Int J Obes Relat Metab Disord. 2002 May;26(5):618-26
references.pmid: 12032744
references.citation: Endocr J. 1995 Apr;42(2):301-5
references.pmid: 7627276
references.citation: Diabetes. 1988 Apr;37(4):405-12
references.pmid: 3378684
references.citation: Lancet. 1999 Jul 31;354(9176):352-3
references.pmid: 10437857
references.citation: Arzneimittelforschung. 1990 Feb;40(2 Pt 1):156-62
references.pmid: 2334455
references.citation: Diabetes. 1992 Apr;41(4):476-83
references.pmid: 1318856
references.citation: Diabetologia. 1983 Dec;25(6):496-501
references.pmid: 6363177
references.citation: Nephron Clin Pract. 2009;112(4):c230-41
references.pmid: 19546582
references.citation: Diabetes Care. 2002 Nov;25(11):2065-73
references.pmid: 12401758
references.citation: N Engl J Med. 1993 Sep 30;329(14):977-86
references.pmid: 8366922
references.citation: Diabetes Res Clin Pract. 2010 Apr;88(1):71-5
references.pmid: 20045213
references.citation: Indian J Med Res. 2007 Mar;125(3):217-30
references.pmid: 17496352
references.citation: Lancet. 1995 Oct 21;346(8982):1080-4
references.pmid: 7564792
references.citation: Lancet. 1998 Sep 12;352(9131):837-53
references.pmid: 9742976
references.citation: N Engl J Med. 1983 Dec 22;309(25):1543-6
references.pmid: 6656849
references.citation: Diabetologia. 1998 Jul;41(7):745-59
references.pmid: 9686914
references.citation: Am J Med. 1985 May;78(5):785-94
references.pmid: 3993659
references.citation: J Am Soc Nephrol. 2007 May;18(5):1540-6
references.pmid: 17409317
references.citation: Kidney Int. 1992 Mar;41(3):600-3
references.pmid: 1573835
references.citation: Diabetes. 1995 Jul;44(7):739-43
references.pmid: 7789641
references.citation: Kidney Int. 1989 Feb;35(2):681-7
references.pmid: 2785225
references.citation: Diabetes Care. 2002 Jul;25(7):1251-2
references.pmid: 12087036
references.citation: Kidney Int. 1991 Dec;40(6):1007-12
references.pmid: 1762301
references.citation: Curr Opin Nephrol Hypertens. 2003 May;12(3):273-82
references.pmid: 12698065
references.citation: Lancet. 1998 Jul 18;352(9123):213-9
references.pmid: 9683226
references.citation: Diabetes Res Clin Pract. 1994 Oct;25(3):169-75
references.pmid: 7851271
references.citation: Nephrol Dial Transplant. 1989;4(10):859-63
references.pmid: 2515489
references.citation: Kidney Int Suppl. 1993 Jan;39:S59-64
references.pmid: 8385721
references.citation: Hypertension. 1998 Jan;31(1 Pt 2):181-8
references.pmid: 9453300
references.citation: Eur J Pharm Sci. 2009 Dec 8;38(5):433-44
references.pmid: 19765654
references.citation: J Clin Invest. 2006 Feb;116(2):288-96
references.pmid: 16453013
references.citation: Am J Physiol Renal Physiol. 2000 Apr;278(4):F554-60
references.pmid: 10751215
references.citation: J Renin Angiotensin Aldosterone Syst. 2008 Dec;9(4):189-95
references.pmid: 19126658